The global vaccine supply chain, explained

A vaccine is not simply a formula. It is a biological product that must be manufactured at industrial scale, kept within precise temperature ranges from the factory to the final dose, shipped across borders through heavily regulated channels, and administered by trained health workers. The system that accomplishes this is one of the most complex in global commerce, and its fragility became visible to the world when it was tested at speed.

How vaccines are made

Vaccine manufacturing is concentrated in a relatively small number of countries. The largest producers include the United States, the European Union, India, and China. A single vaccine often involves components made in multiple countries: the active biological ingredient may be produced in one facility, the adjuvant (a substance that strengthens the immune response) in another, and the final fill-and-finish process, where the product is put into vials and packaged, in a third.

The raw materials required include biological cultures, specialised chemicals, glass vials, rubber stoppers, and filtration equipment. Many of these inputs are themselves produced by a small number of specialist suppliers. A shortage in any single component can halt production of the final product.

The cold chain

Most vaccines must be kept refrigerated throughout their journey from manufacturer to recipient, a requirement known as the cold chain. Some require temperatures well below freezing. Maintaining the cold chain across long distances, through customs clearance, and into remote communities requires specialised refrigerated containers, monitoring equipment, and backup power at storage facilities.

In high-income countries with established infrastructure, the cold chain is largely reliable. In lower-income countries, particularly in parts of sub-Saharan Africa and South Asia, maintaining it is a significant challenge. Doses that are not kept at the right temperature lose effectiveness, which means failures in the cold chain translate directly into failed immunisation campaigns.

Who coordinates the system

The World Health Organization sets standards for vaccine quality, safety, and efficacy. UNICEF is the world's largest buyer of vaccines for developing countries. The Gavi Alliance, a public-private partnership, subsidises vaccine access for lower-income countries. CEPI, the Coalition for Epidemic Preparedness Innovations, funds the development of vaccines against emerging infectious diseases.

COVAX, the global mechanism set up to share COVID-19 vaccines equitably, demonstrated both the ambition and the limitations of international coordination. Wealthy countries purchased vaccines bilaterally and at speed, leaving the shared pool under-supplied. The episode prompted a renewed debate about how to make the system more equitable and resilient for the next pandemic.

What it means for Australia

Australia has limited domestic vaccine manufacturing capacity. For most of its vaccine needs, it depends on imported products from global suppliers. The government has invested in agreements with manufacturers and explored options for domestic production of certain vaccines, partly in response to the supply vulnerabilities exposed in recent years.

Australia also contributes to international vaccine equity programs through foreign aid, both because of its humanitarian commitments and because outbreaks that are not contained elsewhere can eventually reach Australian shores. Investment in global vaccine access is, in this sense, also investment in Australian biosecurity.

The bottom line

The vaccine supply chain is a hidden marvel of global logistics that most people only notice when it fails. Fixing its weak points requires sustained investment in manufacturing capacity, cold chain infrastructure, and the international institutions that coordinate access.

This article was compiled by AI and screened before publishing. See our editorial standards.